ASCO 2022 Conference Intelligence around HER2 Negative Breast Cancer assets

Scope & Objective:

A large Pharmaceutical company, headquartered in the US, wanted DelveInsight to support them by providing a detailed conference coverage of the oncology drug for the indication HER2 negative breast cancer published during ASCO 2022, including the product description, research and developmental activities, product milestones, future plans, and KOL insights.

Congress Coverage Support:

• DelveInsight supported the client by creating a focused conference coverage plan in order to gain an in-depth assessment of the drug along with a detailed understanding of the product's developmental activities and key milestones
• In addition to this DelveInsight also conducted primary research in order to cater to the KOL and Stakeholder insights around the drug
• High-priority sessions were selected for more focused live coverage

Congress Plan:

• The team extracted and classified sessions by priorities
• Captured detailed presentations and understand the business insights
• KITs and KIQs were aligned with the client’s strategic needs

Outcome:

• The deliverables enabled the customer to proactive response to competitor activities at ASCO 2022
• Senior internal stakeholders were timely informed of the latest business updates